A 24-year-old woman is seen in clinic for an initial HIV evaluation and to start antiretroviral therapy. The plan is to start a regimen consisting of dolutegravir plus tenofovir alafenamide-emtricitabine. Her baseline laboratory studies obtained 5 days prior, at the time of her initial HIV diagnosis, show a CD4 count of 220 cells/mm³ and an HIV RNA level of 46,520 copies/mL. An HIV drug resistance genotype is pending.